mAb glucagon receptor blocker suitable for further development

August 4, 2017

(HealthDay)—The glucagon receptor blocker REGN1193, a fully human monoclonal antibody, seems safe and tolerable enough for further development, according to a study published online July 28 in Diabetes, Obesity and Metabolism.

Ana Kostic, Ph.D., from Regeneron Pharmaceuticals in Tarrytown, N.Y., and colleagues gave healthy men and women single ascending doses of REGN1193 ranging from 0.05 mg/kg to 0.6 mg/kg (42 participants) or placebo (14 participants) intravenously. Over 106 days, the authors assessed safety, tolerability, and pharmacokinetics.

The researchers found that REGN1193 was well tolerated overall, with small and transient dose-dependent increases in hepatic aminotransferases. There was no increase in . Across all dose groups, 43 percent of participants on placebo and 57 percent on REGN1193 had hypoglycemia; all episodes of hypoglycemia were asymptomatic, >50 mg/dL, and no treatment or medical assistance was needed. REGN1193 inhibited the glucose increase stimulated by in a dose-dependent manner. The glucagon-induced glucose area under the curve at 0 to 90 minutes was inhibited by the 0.6 mg/kg dose by 80 to 90 percent on days three and 15, while blunting the C-peptide increase. There were independent dose-dependent increases in total glucagon-like peptide 1 (GLP-1), GLP-2, and glucagon with REGN1193, with plasma levels returning to baseline by day 29 in all dose groups.

"The occurrence of transient elevations in serum hepatic aminotransferases observed here and reported with several small molecule antagonists suggest an on-target effect of glucagon receptor blockade," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry, including Regeneron, which is developing REGN1193 and funded the study.

Explore further: Similar defects ID'd for T2DM, chronic pancreatitis and diabetes

More information: Abstract
Full Text

Related Stories

Similar defects ID'd for T2DM, chronic pancreatitis and diabetes

August 2, 2017
(HealthDay)—Patients with type 2 diabetes and those with diabetes secondary to chronic pancreatitis have similarly impaired α-cell responses to oral glucose ingestion and hypoglycemia, according to a study published online ...

G-pen may aid hypoglycemia with type 1 diabetes

February 22, 2016
(HealthDay)—Mini-dose glucagon administered using a stable, ready-to-use G-Pen Mini glucagon may be an effective option for mild to moderate hypoglycemia in adults with type 1 diabetes, according to a study published online ...

Low-carb diet cuts tx effect of glucagon in hypoglycemia

November 7, 2016
(HealthDay)—For patients with type 1 diabetes, a low-carbohydrate diet (LCD) results in lower incremental rises in plasma glucose (PG) after mild hypoglycemia compared with an isocaloric high-carbohydrate diet (HCD), according ...

Glucagon receptor antagonist ups blood pressure in T2DM

February 23, 2017
(HealthDay)—For patients with type 2 diabetes, once-daily treatment with the glucagon receptor antagonist LY2409021 is associated with increases in ambulatory blood pressure (BP), according to a study published online Feb. ...

Glucagon, GLP-1 co-infusion can reduce appetite

June 25, 2014
(HealthDay)—Co-infusion of glucagon and glucagon-like peptide 1 (GLP-1) correlates with a reduction in appetite, and GLP-1 protects against glucagon-induced hyperglycemia in healthy volunteers, according to a study published ...

GI adverse events up with GLP-1 receptor agonists

November 16, 2016
(HealthDay)—Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are associated with increased risk of gastrointestinal adverse events (AEs), with risk varying based on dose, background medications, and type of GLP-1 ...

Recommended for you

Smart mat detects early warning signs of foot ulcers

August 16, 2017
While completing his residency in anesthesiology at Massachusetts General Hospital in the mid-2000s, Jon Bloom saw his fair share of foot amputations among patients with diabetes. The culprit: infected foot ulcers.

The best place to treat type 1 diabetes might be just under your skin

August 14, 2017
A group of U of T researchers have demonstrated that the space under our skin might be an optimal location to treat type 1 diabetes (T1D).

New measure of insulin-making cells could gauge diabetes progression, treatment

August 10, 2017
Researchers at the University of Wisconsin-Madison have developed a new measurement for the volume and activity of beta cells, the source of the sugar-regulating hormone insulin.

Pioneering immunotherapy shows promise in type 1 diabetes

August 9, 2017
It may be possible to 'retrain' the immune system to slow the progression of type 1 diabetes, according to results of a clinical trial published today in the journal Science Translational Medicine.

Online team-based game helps patients with diabetes lower blood glucose

August 8, 2017
Researchers from Brigham and Women's Hospital and the Veterans Affairs Boston Healthcare System have found that an online, team-based game designed to teach patients about diabetes self-management had a sustained and meaningful ...

Oxidative stress biomarkers don't always signal diabetes risk

August 7, 2017
High levels of compounds found in the body that are commonly associated with oxidative damage may actually be a good sign for some people, according to a recent review of multiple human studies led by an epidemiologist at ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.